CureVac NV (5CV) - Total Assets
Based on the latest financial reports, CureVac NV (5CV) holds total assets worth €1.14 Billion EUR (≈ $1.33 Billion USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore cash flow to debt ratio of CureVac NV to assess how comfortably operating cash covers total debt obligations.
CureVac NV - Total Assets Trend (2018–2024)
This chart illustrates how CureVac NV's total assets have evolved over time, based on quarterly financial data. See CureVac NV (5CV) shareholders funds for net asset value and shareholders' equity analysis.
CureVac NV - Asset Composition Analysis
Current Asset Composition (December 2024)
CureVac NV's total assets of €1.14 Billion consist of 65.6% current assets and 34.4% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 60.0% |
| Accounts Receivable | €14.08 Million | 1.8% |
| Inventory | €541.00K | 0.1% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €12.69 Million | 1.6% |
| Goodwill | €12.46 Million | 1.6% |
Asset Composition Trend (2018–2024)
This chart illustrates how CureVac NV's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see CureVac NV (5CV) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: CureVac NV's current assets represent 65.6% of total assets in 2024, an increase from 58.2% in 2018.
- Cash Position: Cash and equivalents constituted 60.0% of total assets in 2024, up from 17.0% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, a decrease from 4.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 1.8% of total assets.
CureVac NV Competitors by Total Assets
Key competitors of CureVac NV based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Syndax Pharmaceuticals Inc
NASDAQ:SNDX
|
USA | $472.67 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $506.75 Million |
|
Chengdu Kanghua Biological Products
SHE:300841
|
China | CN¥3.94 Billion |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
|
China | CN¥1.84 Billion |
CureVac NV - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.70 | 6.20 | 5.61 |
| Quick Ratio | 3.69 | 6.19 | 5.55 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €636.94 Million | €490.36 Million | €1.14 Billion |
CureVac NV - Advanced Valuation Insights
This section examines the relationship between CureVac NV's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.01 |
| Latest Market Cap to Assets Ratio | 1.10 |
| Asset Growth Rate (YoY) | 1.8% |
| Total Assets | €802.83 Million |
| Market Capitalization | $885.32 Million USD |
Valuation Analysis
Above Book Valuation: The market values CureVac NV's assets above their book value (1.10x), reflecting positive investor sentiment about the company's future prospects.
Positive Asset Growth: CureVac NV's assets grew by 1.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for CureVac NV (2018–2024)
The table below shows the annual total assets of CureVac NV from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €802.83 Million ≈ $938.59 Million |
+1.85% |
| 2023-12-31 | €788.25 Million ≈ $921.55 Million |
-8.39% |
| 2022-12-31 | €860.47 Million ≈ $1.01 Billion |
-25.71% |
| 2021-12-31 | €1.16 Billion ≈ $1.35 Billion |
-23.36% |
| 2020-12-31 | €1.51 Billion ≈ $1.77 Billion |
+1057.06% |
| 2019-12-31 | €130.62 Million ≈ $152.71 Million |
+3.95% |
| 2018-12-31 | €125.66 Million ≈ $146.91 Million |
-- |
About CureVac NV
As of December 18, 2025, CureVac N.V. was acquired by BioNTech SE. CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). The company's portfolio includes clinical and preclinical candidates for various disease indications in prophylactic vaccines, oncology, and molecular therapy. It also delivers optimized mRN… Read more